The safety assessment for marketing purposes of genetically modi ed (GM) foods in the 15 Member States of the European Union (EU) is based on the Novel Foods and Novel Food Ingredients Regulation adopted in May 1997. Before a GM food can be approved under the Regulation, it must satisfy three criteria: Gm food must be safe, it must not mislead the consumer and it must be nutritionally adequate. The EU Scienti c Committee on Food has published a set of guidelines describing the type of information expected from a company in support of an application for approval of a GM food or food ingredient. Despite this rigorous procedure and there being no evidence of harm resulting from the consumption of GM foods worldwide, there is essentially no market in the EU for such product s at present. Possible reasons for this are discussed and the view put forward that the market for GM foods will change only when there are more clearly perceived consumer bene ts.
THE REGULATORY SYSTEM IN THE EUROPEAN UNION
In the European Union (EU), the safety of genetically modi ed (GM) food is controlled by the Novel Foods and Novel Food Ingredients Regulation 258/97/EC (2) . The Regulation came into effect on 15th May 1997 and introduced a mandatory premarket safety assessment for all novel foods. In this Regulation, a novel food is de ned as a food or food ingredient which has not been used for human consumption to a signi cant degree within the European Community. For the purpose of this Regulation, novel foods are divided into 6 categories, 2 being concerned with foods derived from recombinant DNA technology. These 2 categories are, rst, foods and food ingredients containing or consisting of GM organisms, for example, tomatoes modi ed to delay ripening and, second, foods or food ingredients produced from but not containing GM organisms such as soya or corn oils.
Before a novel food can be approved under the Regulation, it must satisfy 3 criteria-it must not: present a danger to the consumer, mislead the consumer, or differ from a food it is intended to replace to such an extent that its normal consumption would be nutritionally disadvantageous to the consumer.
The assessment procedure is delegated to the 15 Member States of the EU. A company wishing to market a novel food would apply to the Member State where it rst intended to market the product. The Member State has 90 days in which to carry out a safety assessment based on the information supplied by the company, and forward its opinion to the European Commission. The other Member States having received details of a favourable opinion from the Commission and a body of data supplied in support of the application, have 60 days in which to agree or disagree. If there are disagreements, then the application is considered by the Standing Committee of Food (representing all Member States) where a decision is made on a quali ed majority vote. The Standing Committee will also seek the advice of the EU Scienti c Committee on Food (SCF) on any issues relating to public health.
The SCF produced Guidelines in 1997 setting out the type of information expected in support of an application for approval of a novel product (1) . Products derived from GMOs were divided into 3 classes: those from GM plants and their products, those from GM animals and their products, and those from GM microorganisms and their products. In each of these classes, the source of the novel food may have had a history of food use in the EU or no such history.
A structural scheme has been devised to identify the types of information that are likely to be required to establish the safety of the previously mentioned classes. There are 13 categories of information although only 1 class would require all of these-a live yogurt produced using GM microorganism(s). The 13 information requirements are listed in Table 1 . For each information category there is a decision tree to allow food companies to decide whether they have enough data to satisfy each requirement.
The information requirements for each GM food category are shown in Table 2 .
SUBSTANTIAL EQUIVALENCE
The concept of substantial equivalence was introduced by OECD with particular reference to foods produced by modern biotechnology (6) . The notion embodies the idea that existing organisms used as food sources (and the foods themselves) can serve as a basis for comparison when assessing the safety of a food or food component that has been modi ed or is new. The principle is that if a new food or food component is found to be substantially equivalent to an existing food or food component by chemical analysis, then it can be treated in the same manner with respect to safety, bearing in mind that establishment of substantial equivalence is not a safety or nutritional assessment in itself but an approach to compare a potential new food with its conventional counterpart. 129 0192-6233/02$3.00 $0.00 TABLE 1.-Information required to support applications to market genetically-modi ed foods in the European Union.
I. Speci cation of the novel food II. Effect of the production process applied to the novel food III. History of the organism used as a source of the novel food IV. Effect of the genetic modi cation on the properties of the host organism V. Genetic stability of the GMO VI. Speci city of expression of novel genetic material VII. Transfer of genetic material from the GMO VIII. Ability of GM microorganism to survive in and colonise the human gut IX. Anticipated intake/extent of use of the novel food X. Information from previous human exposure to the novel food or its source XI. Nutritional information on the novel food XII. Microbiological information on the novel food XII. Toxicological information on the novel food There are some categories of food derived from GMOs that are substantially equivalent to their conventional counterparts in that they cannot be distinguished by chemical analysis such as corn and canola oils or hydrolysed products of corn starch. Other foods derived from genetically modi ed organisms may be substantially equivalent apart from the newly introduced genes and their protein products so that safety assessments can be concentrated on the new DNA and proteins. The establishment of substantial equivalence in GM plants depends upon morphological features and agronomic data together with chemical analysis of critical nutrients (both macro-and micro-) and any critical toxicants and antinutritional factors.
The scienti c justi cation for substantial equivalence has been questioned (5) . Because it avoids a full safety assessment while regulatory committees have been increasingly demanding in the data they require to establish substantial equivalence. The absence of differences in a limited number of chemical analyses used to establish substantial equivalence does not eliminate the possibility of an inadvertent effect that may have health consequences. Consequently there are moves to develop new technologies such as DNA array methods, proteomics, and metabolic pro ling methods that would allow a more discerning analysis (3).
TOXICOLOGICAL REQUIREMENTS
Foods have traditionally been regarded as natural, benecial, and necessary products whose safety and nutritional value need not be questioned. Regulatory approaches to food safety have re ected this attitude and have focused on food additives, processing aids, and contaminants of natural or industrial origin. Thus, foods have not been systematically subjected to toxicological evaluation, except in rare cases I, II, III, IV, V, VI, VII, IX, XI, XII, XIII  GM Animals  1) I, II, III, IV, V, VI, VII, IX, X, XI, XII, XIII  2) I, II, III, IV, V, VI, VII, IX, XI, XII, XIII  GM Microorganisms 1) I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII, XIII 2) I, II, III, IV, V, VI, VII, VIII, IX, XI, XII, XIII a 1) represents that host used for genetic modi cation has a history of use as food or as a source of food in the EU.
b 2) represent s that host used for genetic modi cation has no history of use as food or as a source of food in the EU.
where acute toxic effects have been reported such as solanine in potatoes. The assessment of the wholesomeness of GM foods and food ingredients presents a number of scienti c challenges. Conventional toxicological evaluation methods cannot be applied to foods. For example, the amount of food to be incorporated into diet for animal feeding studies without perturbing its nutritional balance makes the use of conventional safety factors inappropriate for risk assessment for any product intended for use as a food or a major food ingredient. Therefore, alternative approaches for the testing and assessment of the wholesomeness of foods and major food ingredients are needed.
In principle the toxicological requirements for GM foods need to be considered on a case-by-case basis. However, experience gained in the assessment of novel foods over the last 4 years has demonstrated the need for more precise guidance on the toxicological information required to assess the safety of GM foods and food ingredients. Such guidelines are currently being constructed by the SCF in which safety studies will be required on both the novel proteins introduced into the GMO and the whole GMO.
Studies on the novel proteins will include protein characterisation, a search for homology to known proteins, protein stability and digestibility, and toxicity studies in vivo (a shortterm feeding study in rodents). Information on the GMO will rely on chemical analyses of toxicologically relevant compounds and modern pro ling techniques currently under development. Toxicological studies with the GM products intended to be used as food will require a subchronic study in rodents (90 days) as a minimum.
LABELLING OF GM FOODS IN EUROPE
There is a mandatory requirement for the labelling of GM foods and food ingredients in the European Union. This is in contrast to the position in the United States where, until recently, there was no requirement for labelling to indicate a GM food component. Even then, following a statement from the White House in May 2000, the FDA was charged only with developing guidelines for the voluntary labelling of food products as containing or not containing GM products. The EU Regulation 258/97/EC sets out the rules for authorisation and labelling of GMO-derived food products, and a later Regulation (1139/98/EC) serves as a model for labelling within the EU and for the requirements for food labelling required by 258/97/EC. It is normal to set a de minimus value, below which a declaration is not required. This value is usually arrived at pragmatically, taking account of the level of contamination likely, the degree to which contamination represents a health hazard and the availability of robust methods of detection available to enforce the legislation. In the case of GM foods, labelling provisions have been amended by Commission Regulation 49/2000 to provide a 1% adventitious contamination level below which the presence of GM material does not have to be declared. Regulation 50/2000 deals with speci c labelling requirements for foodstuffs and food ingredients containing additives and avourings derived from GMOs.
Although GM foods, when rst introduced into the United Kingdom, were labelled as having a GM origin, this did not cause signi cant consumer concern. However, today it is difcult to avoid the conclusion that the labelling of GM food products serves to fuel consumer prejudice, hence the almost complete disappearance of the market.
THE SOCIAL ACCEPTANCE OF GM FOODS IN EUROPE
Novel foods resulting from the application of recombinant DNA technology were available in British supermarkets from 1994 onwards. In that year, cheese made using chymosin, from a GM microorganism rather than the traditional rennet, went on sale. In 1996, tomato paste made from tomatoes modi ed to reduce the action of the enzyme polygalacturanase that causes the fruit to soften, and manufactured foods containing soya and maize ingredients from plants genetically modi ed to confer herbicide tolerance or insect resistance were marketed.
The introduction of these products was not without its problems. The cheese and tomato pastes were labelled, in the latter case with large lettering drawing attention to the fact that the paste was made from GM tomatoes. There appeared to be very little hostility to the products; indeed over 2 million cans of tomato paste were sold, and the labelling allowed consumers a choice between GM and traditional varieties. Public concern was triggered by the introduction particularly of the soya products from GM plants into about 40% of manufactured foods without appropriate labelling and therefore lack of choice. This was seized on by lobby groups to develop a very successful campaign through the press, radio, and television to create public concern about the environmental safety of GM crops and the safety of GM foods.
Early in 1999, one relatively small chain of food retailers decided to respond to this consumer concern by guaranteeing that it would eliminate all GM ingredients from its own-brand foods within a few months and later reported a considerable increase in its food sales. This caused all the major supermarkets to review their policies regarding the selling of GM foods and after consulting focus groups of consumers all decided to eliminate GM ingredients from their own-brand products. The success of this strategy encouraged the lobby groups to pressure the supermarkets to guarantee the removal of GM ingredients from animal feed used to source the animal products sold in their stores-meat, poultry, eggs, and milk. This has been partially successful but depends on identity preservation of GM and non-GM crops and does not come without an additional cost. In any event, it is now extremely difcult to purchase any food containing a GM ingredient in a British supermarket and this attitude is re ected throughout the EU.
The notion that the introduction of GM foods would elicit a public backlash predates the introduction of such items into our diet. The reasons for consumers distrusting the technology and its products operates at various levels and these have been discussed and reviewed extensively (4, 7, 8) . At the ethical level there are concerns about scientists "playing God" by tinkering with the stuff of life, that genetic modi cation breaches the natural barriers and boundaries between species which Nature has set up through the process of evolution and that genetic modi cation distorts mankind's relationship with the rest of nature. There are also concerns that the technology is an expensive one and will not be available to poor farming communities and may even distort the economies of third-world countries.
At the consumer level there are worries about the future safety of the technology; it is not a worry about the technology but rather about its consequences. The risks envisaged are often catastrophic in nature, for example the creation of superweeds from the escape of engineered genes in crop plants into wild relatives or the development of serious illness in the human population at some long time in the future, from the consumption of GM foods. The problem is that in theory any activity could lead to catastrophic consequences and the UK population has been sensitised by the emergence of new variant CJD by apparent consumption of meat from cows infected by BSE, in spite of assurances to the contrary. This has resulted in an increased lack of trust in Government pronouncements and the scienti c advice that Government receives from its Advisory Committees.
Risks are unavoidably involved in any activity but the question is whether irresponsible and unjusti able risks are being taken. To counter this view it is possible to point to the fact that the possible harmful effects seem to be entirely speculative; there have been no reports of illness from the consumption of such foods. Additionally, the stringent regulations that have been described and operate across the developed world would eliminate many of the horror scenarios described for the future by opponents of the technology. Perhaps what is required in Europe to restore a market for GM foods and food ingredients is some clear perception of consumer bene ts. Most of the developments in crop breeding so far have been to improve productivity-output traits, that have very little impact on either the price of manufactured foods or their quality. So, even if the risk is only perceived to be small, why take that risk in the absence of clear bene ts? In the next decade, it is likely that input traits will be engineered into plants to bring signi cant bene ts to the consumer and move the risk-bene t equation in favour of bene ts.
